Fly News Breaks for December 16, 2019
Dec 16, 2019 | 13:25 EDT
Guggenheim analyst Yatin Suneja raised Buy rated Axsome Therapeutics' price target to $158 from $65 after the company announced positive topline Phase 3 GEMINI data for AXS-05 in major depressive disorder.
News For AXSM From the Last 2 Days
There are no results for your query AXSM